Skip to main content

Table 1 Cell line characteristics, BRAF V600E mutational status and viability after sorafenib treatment for 48 hours of all thyroid carcinoma cell lines examined

From: Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status

Cell line Origin BRAFV600E-mutation IC50 sorafenib (μM) Lowest effective concentration (μM)
BHT101 Papillary Heterozygous 2.1 1.0
B-CPAP Papillary Heterozygous 1.85 1.0
TPC1 Papillary No 2.6 0.05
FTC133 Follicular No 2.9 1.0
FTC236 Follicular No 3.2 0.5
FTC238 Follicular No 4.2 0.01
ML1 Follicular No 2.95 2.0
TT2609 Follicular No 3.05 1.0
SW1736 Anaplastic Heterozygous 3.25 1.0
HTh83 Anaplastic No 3.95 2.0
C643 Anaplastic No 3.2 0.01
HTh7 Anaplastic No 3.1 2.0